Abstract: Renal and pancreatic cysts and tumors are the most common visceral manifestations of von Hippel-Lindau (VHL) disease, a heritable multisystem cancer syndrome characterized by development of a variety of malignant and benign tumors. We report a case of a VHL patient with multiple renal cystic and complex cystic/solid lesions. The patient underwent 68 Ga-DOTA-TATE-PET/CT showing intensely increased activity by a solid lesion which demonstrated enhancement on both CT and MRI scans, raising high suspicion for malignancy. The presented case indicates application of SSTR-imaging using 68 Ga-DOTA-conjugated peptides in VHL-patients and emphasizes the need for cautious interpretation of renal parenchyma 68 Ga-DOTATATE activity.
FIGURE 1.
We report on a 45-year-old man with known history of von Hippel-Lindau (VHL) disease affecting several organs including cerebellar and spinal hemangioblastomas, pancreatic neuroendocrine tumors (NETs), and kidney lesions leading to total left nephrectomy. On annual follow-up, the patient underwent i.v.-contrast CT of the abdomen which showed multiple cystic and complex solid/cystic lesions throughout the right kidney (A and B: axial and coronal post-contrast CT images, yellow arrows) with a solid enhancing (average H.U.: 158) mass seen on the superior pole and measuring 2.4 cm Â 2 cm (A and B: red arrow). Subsequently, MRI scan confirmed the right kidney lesions (C: yellow arrows) including the enhancing solid mass in the upper pole (C: axial post-contrast T1 image, red arrow). The patient underwent whole-body PET/CT scan using 68 Ga-DOTA-TATE which showed multiple photopenic areas in the right kidney (D and E: axial and coronal fused PET/CT images, yellow arrows), corresponding to cystic lesions. However, the upper pole solid mass, which was enhanced on both CT and MRI scans, demonstrated intensely increased (SUV max : 26.3) 68 Ga-DOTA-TATE activity (D and E: white arrow), suggesting cell-surface overexpression of somatostatin receptors (SSTRs) and raising high suspicion of malignancy. Unfortunately, the patient refused to pursue with surgical treatment and nephron-sparing resection of this mass aiming to preserve function of the solitary right kidney was not performed. VHL is an autosomal dominantly inherited familial cancer syndrome characterized by development of a variety of benign and malignant tumors, which is associated with a germline mutation of the VHL tumor suppressor gene on the short arm of chromosome.
1,2 VHL's spectrum of manifestations is broad with 40 different lesions in 14 different organs. 3 Of the most common visceral VHL manifestations are renal cysts and renal cell carcinoma (RCC), which account for the most common causes of death in VHL patients. 3, 4 Kidney malignancies often remain asymptomatic for long intervals while macroscopically normal-appearing renal tissue can contain microscopic tumoral foci. 5 Thus, serial imaging with different modalities is critical for early detection of any malignant transformation of seemingly benign cysts, enabling less morbid operations such as nephron-sparing resection. Since many VHL manifestations such as hemangioblastomas or pancreatic NETs are known to overexpress SSTRs, they can be effectively targeted and monitored with radiolabeled SST analogues. 6, 7 The introduction of 68 Ga-DOTA-conjugated peptides (SST analogues) into clinical practice enabled SSTR imaging with PET and evolves as the imaging standard of reference for the detection and characterization of SSTR-positive tumors, with high potential in VHL disease. 8, 9 In the current case,
68
Ga-DOTA-TATE-PET/CT confirmed SSTR overexpression by the enhancing solid renal lesion, raising high suspicion of RCC or pancreatic NET metastases. The differential diagnosis should also include primary renal carcinoid tumors, which are extremely rare kidney tumors exhibiting SSTRs cell-surface overexpression.
